Skip to main content


  • Doctor (MD) at the Faculty of Medicine, University of Oslo


  • PhD fellow, Clinic for rheumatology, outpatient clinic and research, Diakonhjemmet Hospital

Field of interest

  • Rheumatology
  • Immunosuppressive medications
  • Personalized medicine
  • Therapeutic drug monitoring
  • Vaccines
  • Randomized controlled trials


This email address is being protected from spambots. You need JavaScript enabled to view it.


visiting address

Diakonhjemmet hospital
Reidar Kobros vei 8
0370 Oslo

Postal address

Diakohjemmet hospital
PO Box 23 Vinderen
0319 Oslo


WP6 - Dechiphering long-term outcomes


The Norwegian register for antirheumatic drugs

Project Manager:
Tore K. Kvien
WP2 - PPhenotyping for personalized medicine


Immunological response to COVID-19 vaccine in patients on immunosuppressive treatment

Project Manager:
Guro Løvik Goll
WP1 - Optimized medical interventions


Therapeutic drug monitoring in patients with rheumatoid arthritis (RA-DRUM)

Project Manager:
Silje Watterdal Syversen
WP1 - Optimized medical interventions


Maximizing the effect of prescription drugs in rheumatoid arthritis 

Project Manager:
Espen A. Haavardsholm


Publications taken from the National Science Archive (NVA):

Dynamics of SARS-CoV-2 immunity after vaccination and breakthrough infection in rituximab-treated rheumatoid arthritis patients: a prospective cohort study

Hassen Kared, Ingrid Jyssum, Amin Alirezaylavasani, Ingrid Marie Egner, Trung The Tran, Lisa Tietze

Frontiers in Immunology


Incidence and outcome of COVID-19 following vaccine and hybrid immunity in patients on immunosuppressive therapy: identification of protective post-immunisation anti-RBD antibody levels in a prospective cohort study

Hilde Sofie Sager Ørbo, Kristin Reine Hammersbøen, Joseph Sexton, Ingrid Jyssum, Anne Therese Tveter, Ingrid Egeland Christensen

RMD Open


Adalimumab serum levels and anti-drug antibodies: associations to treatment response and drug survival in inflammatory joint diseases

Ingrid Jyssum, Johanna Gehin, Joseph Sexton, Eirik Kristianslund, Yi Hu, David Warren



Humoral immune response to SARS-CoV-2 vaccination in patients with inflammatory bowel disease on immunosuppressive medication: association to serum drug levels and disease type

Kristin Kaasen Jørgensen, Marte Lie Høivik, Adity Chopra, Jurate Saltyte Benth, Petr Ricanek, Bjørn Allan Moum

Scandinavian Journal of Gastroenterology


Four SARS-CoV-2 vaccine doses or hybrid immunity in patients on immunosuppressive therapies: a Norwegian cohort study

Kristin H. Bjørlykke, Hilde Sofie Sager Ørbo, Anne Therese Tveter, Ingrid Jyssum, Joseph Sexton, Trung Tran

The Lancet Rheumatology


Immunogenicity and safety of a three-dose SARS-CoV-2 vaccination strategy in patients with immune-mediated inflammatory diseases on immunosuppressive therapy

Silje Watterdal Syversen, Ingrid Jyssum, Anne Therese Tveter, Joseph Sexton, Ingrid Egeland Christensen, Trung Tran

RMD Open


The persistence of anti-Spike antibodies following two SARS-CoV-2 vaccine doses in patients on immunosuppressive therapy compared to healthy controls—a prospective cohort study

Ingrid Egeland Christensen, Ingrid Jyssum, Anne Therese Tveter, Joseph Sexton, Trung Tran, Siri Mjaaland

BMC Medicine


Immunogenicity and Safety of Standard and Third-Dose SARS-CoV-2 Vaccination in Patients Receiving Immunosuppressive Therapy

Silje Watterdal Syversen, Ingrid Jyssum, Anne Therese Tveter, Trung Tran, Joseph Sexton, Sella Aarrestad Provan

Arthritis & Rheumatology


Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study

Ingrid Jyssum, Hassen Kared, Trung Tran, Anne Therese Tveter, Sella Aarrestad Provan, Joseph Sexton

The Lancet Rheumatology